| | Characteristics | 90-day survival | | Alive | Dead | | () | () |
| | Age (Mean (±SD)) | 68.8 (16.7) | 71.2 (13.9) | | Gender, Male ((%)) | 24 (61.5) | 5 (55.6) | | Comorbidities ((%)) | | | | Ischaemic heart disease | 9 (23.7) | 1 (11.1) | | Congestive cardiac failure | 3 (7.9) | 0 (0) | | Cerebrovascular disease | 2 (5.3) | 0 (0) | | Type II diabetes mellitus | 7 (18.4) | 0 (0) | | Renal impairment | 7 (18.4) | 2 (22.2) | | Hypertension | 13 (34.2) | 5 (55.5) | | Hyperlipidaemia | 7 (18.4) | 1 (11.1) | | Smoker | 7 (18.4) | 0 (0) | | Drug history ((%)) | | | | Aspirin | 3 (7.9) | 0 (0) | | Statin | 9 (23.7) | 1 (11.1) | | Beta blocker | 4 (10.5) | 3 (33.3) | | ACEI | 9 (23.7) | 2 (22.2) | | Diuretic | 6 (15.8) | 2 (22.2) | | Calcium channel blocker | 6 (15.8) | 3 (33.3) | | Risk scores (median (min–max)) | | | | ASA score | 3 (1–5) | 4 (3–4.5) | | Lee cardiac risk score | 2 (1–4) | 2 (2–4) |
|
|